It is currently Mon Sep 26, 2016 3:35 am

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya ‘prevents activation of key immune cells’

In a recent study entitled Myeloid Cells As Target Of Gilenya Action In Multiple Sclerosis, a team of scientists investigated the impact of MS treatment Gilenya on the reactivity of myeloid cells, a key group that comprises several immune cells that are activated in MS patients and the underlying cause of the condition. The study was published in the journal Neurology...Read more - http://www.ms-uk.org/MSnews
Read more : Gilenya ‘prevents activation of key immune cells’ | Views : 1052 | Replies : 0


No conclusions over best drug for Multiple Sclerosis

Two studies - one from France, the other from Denmark - came to conflicting conclusions about whether Tysabri or Gilenya offers better efficacy, researchers have reported here... Read More - http://www.ms-uk.org/MSnews
Read more : No conclusions over best drug for Multiple Sclerosis | Views : 1138 | Replies : 0


Long-term efficacy of Gilenya reinforced by new analysis

Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya. The analysis evaluated the proportion of Gilenya patients with relapsing-remitting multiple sclerosis (RRMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years... Read More - http://www.ms-uk.org/MSnews
Read more : Long-term efficacy of Gilenya reinforced by new analysis | Views : 943 | Replies : 0


Gilenya found to be effective ‘for up to three years’

An encouraging new analysis reveals Gilenya is an effective MS therapy for a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centres in America... Read More - http://www.ms-uk.org/gilenya
Read more : Gilenya found to be effective ‘for up to three years’ | Views : 1220 | Replies : 0


Third case of PML reported to Novartis

Novartis has been notified of a third case of progressive multifocal leukoencephalopathy (PML) in a patient with relapsing multiple sclerosis (MS) treated with Gilenya... Read More - http://www.ms-uk.org/gilenya
Read more : Third case of PML reported to Novartis | Views : 1389 | Replies : 0


FDA issues PML warning for MS patients taking Gilenya

Following reports of progressive multifocal leukoencephalopathy among patients taking Gilenya for multiple sclerosis, the FDA has issued a warning of possible infection for those prescribed the immunosuppressant drug.... Read More - http://www.ms-uk.org/gilenya
Read more : FDA issues PML warning for MS patients taking Gilenya | Views : 1293 | Replies : 0


Study finds lesions may compromise heart rate in Gilenya....

Study finds lesions may compromise heart rate in Gilenya patients

In a recent study published in the Journal PLOS One, a team of researchers found that the autonomic cardiovascular dysfunction in MS patients with delayed heart rate re-acceleration upon Gilenya-initiation suggest MS-related central autonomic lesions may compromise heart rate re-acceleration..... Read More - http://www.ms-uk.org/gilenya
Read more : Study finds lesions may compromise heart rate in Gilenya.... | Views : 1192 | Replies : 0


Gilenya ‘found to have long-term positive effects’

A new study published in the Journal of Neurology, Neurosurgery and Psychiatry has found long-term Gilenya therapy can maintain a low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). The study, Long-Term (up to 4.5 years) Treatment With Fingolimod (Gilenya) In Multiple Sclerosis: Results From The Extension Of The Randomised TRANSFORMS Study, was conducted by an international team of researchers..... Read More - http://www.ms-uk.org/gilenya
Read more : Gilenya ‘found to have long-term positive effects’ | Views : 1477 | Replies : 0


Researchers suggest short transition period....

Researchers suggest short transition period between RRMS therapies

A team led by researchers at the University Hospital Basel in Switzerland say they have found a short period of eight to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from Tysabri (natalizumab) to Gilenya (fingolimod) therapy.... Read More - http://www.ms-uk.org/gilenya
Read more : Researchers suggest short transition period.... | Views : 1268 | Replies : 0


MS mom needs medicine

Dear all,

First of all I want to express my admiration for your courage in facing MS and your kindness in supporting the patients.

My name is Hadeel and I have created this account on behalf of my mother "Hedaya" who has been diagnosed with MS in 2007.
We are Palestinians from Gaza, but my mother lives in the United Arab Emirates (UAE), and I am currently studying in Germany.

In July 2014, my father ...
Read more : MS mom needs medicine | Views : 1044 | Replies : 0


 

Login  •  Register


Statistics

Total posts 234246 • Total topics 25182 • Total members 16406


Contact us | Terms of Service